Servier will acquire Day One for $2.5 billion in order to develop a pipeline of cancer drugs
In addition to Ojemda, an authorized treatment for some childhood brain tumors that are difficult to cure, the planned acquisition would provide Servier with a few investigational medications undergoing human development.
